A5052524269- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Advanced Causal Inference Techniques
- CAR-T cell therapy research
- Global Cancer Incidence and Screening
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Statistical Methods in Clinical Trials
- Chronic Myeloid Leukemia Treatments
- Ethics in Clinical Research
- Adrenal and Paraganglionic Tumors
- Mycobacterium research and diagnosis
- Pituitary Gland Disorders and Treatments
- Cancer, Hypoxia, and Metabolism
- Virus-based gene therapy research
- Cancer Mechanisms and Therapy
- Viral-associated cancers and disorders
- Hematological disorders and diagnostics
- Silicon Carbide Semiconductor Technologies
- Malaria Research and Control
- Acute Lymphoblastic Leukemia research
Hôpital Lyon Sud
2017-2024
Hospices Civils de Lyon
2016-2022
Université Claude Bernard Lyon 1
2018-2022
Centre de Recherche en Cancérologie de Lyon
2020
Inserm
2020
Centre Léon Bérard
2016
Aim: This study aimed to identify the clinical, radiological and prognostic features of primary adrenal lymphoma (PAL) in order diagnose disease more accurately. Materials methods: A retrospective multi-centre was conducted on biological as well treatment overall survival outcomes PAL. Results: Between 1994 2014, 28 patients from five regions eastern France were diagnosed with lymphoma. The revealing symptoms a worsening general state (77%), weight loss (77%) abdominal pain (42%). Biological...
Summary Composite and sequential lymphomas involving both classical Hodgkin lymphoma (CHL) primary mediastinal B‐cell (PMBCL) are rare phenomena. Beyond the relevant biological interest raised by these cases, treatments outcome data poorly covered in recent literature. This retrospective analysis describes pathological clinical characteristics of 10 composite 15 cases included after a central review. At diagnosis, 70% presented disseminated extranodal disease. Among lymphomas, 12 were CHL at...
Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged as key players therapy, we sought to evaluate the evolution HLA-DR expression on (mHLA-DR) before after commercial T-cell infusion a cohort (n = 103) R/R LBCL its association adverse events treatment response. Cy-Flu-based lymphodepletion (LD) upregulated mHLA-DR 79% cases,...
In spite of spectacular advances in the treatment multiple myeloma, a majority patients will die from this disease or related complications. While great amount focus has been dedicated to development novel therapies, little attention paid latter stages patient follow-up. order describe management during critical period as well immediate causes and circumstances death, we have analyzed single center series 100 diagnosed with myeloma who died between 2016 2021. Patients received median 3 lines...
We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy safety profile of rituximab (375 mg/m2) in combination with etoposide (300 ifosfamide (1500 at 2, 3, or 4-week intervals. Median age was 79 years (range, 64–92). The median number previous line 1 (range 1–8). Patients received a six cycles (1–12). Fourteen (19%) presented partial 14 complete...